Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:DRRXNASDAQ:EVOKNASDAQ:MTEXNASDAQ:UBX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDRRXDURECT$0.64+10.8%$0.74$0.52▼$1.88$20.02M0.6665,258 shs762,815 shsEVOKEvoke Pharma$3.23+3.9%$2.85$1.94▼$12.32$4.82M0.16122,802 shs10,303 shsMTEXMannatech$10.59+5.9%$9.84$6.75▼$16.49$20.13M1.064,391 shs453 shsUBXUnity Biotechnology$0.90+0.9%$1.21$0.85▼$3.10$15.37M1.28122,231 shs91,355 shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDRRXDURECT-1.19%-3.00%-27.24%-26.24%-51.50%EVOKEvoke Pharma-5.76%+13.09%+32.34%-36.40%-44.86%MTEXMannatech+6.95%-2.78%+21.39%-13.83%+33.16%UBXUnity Biotechnology-2.61%-20.71%-3.15%-60.35%-44.69%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationDRRXDURECT0.358 of 5 stars0.02.00.04.40.00.00.0EVOKEvoke PharmaN/AN/AN/AN/AN/AN/AN/AN/AMTEXMannatech0.8333 of 5 stars0.05.00.80.00.61.70.0UBXUnity Biotechnology3.9794 of 5 stars3.53.00.04.71.10.81.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceDRRXDURECT 2.00HoldN/AN/AEVOKEvoke Pharma 0.00N/AN/AN/AMTEXMannatech 0.00N/AN/AN/AUBXUnity Biotechnology 3.00Buy$5.33491.93% UpsideCurrent Analyst Ratings BreakdownLatest EVOK, UBX, DRRX, and MTEX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/23/2025UBXUnity BiotechnologyChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$4.00 ➝ $4.004/23/2025UBXUnity BiotechnologyHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$4.00 ➝ $4.003/27/2025DRRXDURECTHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral3/25/2025UBXUnity BiotechnologyChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$6.00 ➝ $4.003/24/2025UBXUnity BiotechnologyHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$8.00 ➝ $4.003/10/2025UBXUnity BiotechnologyChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$6.00 ➝ $6.003/10/2025UBXUnity BiotechnologyHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$8.00 ➝ $8.00(Data available from 5/8/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookDRRXDURECT$2.03M9.86N/AN/A$0.50 per share1.29EVOKEvoke Pharma$10.25M0.47N/AN/A($9.26) per share-0.35MTEXMannatech$117.87M0.17N/AN/A$5.64 per share1.88UBXUnity Biotechnology$240K64.62N/AN/A$1.69 per share0.53Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateDRRXDURECT-$27.62M-$0.27N/AN/AN/A-198.58%-300.62%-65.17%5/12/2025 (Estimated)EVOKEvoke Pharma-$7.79M-$4.40N/A∞N/A-71.32%-308.49%-53.66%5/13/2025 (Estimated)MTEXMannatech-$2.24M$1.33N/A∞N/A-1.26%-15.62%-3.76%5/13/2025 (Estimated)UBXUnity Biotechnology-$39.86M-$1.62N/AN/AN/AN/A-119.70%-45.86%5/13/2025 (Estimated)Latest EVOK, UBX, DRRX, and MTEX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2025Q1 2025EVOKEvoke Pharma-$0.33N/AN/AN/A$3.32 millionN/A5/13/2025Q1 2025UBXUnity Biotechnology-$0.43N/AN/AN/AN/AN/A5/12/2025Q1 2025DRRXDURECT-$0.14N/AN/AN/A$0.29 millionN/A4/22/2025Q1 2025UBXUnity Biotechnology-$0.43-$0.43N/A-$0.43N/AN/A3/26/2025Q4 2024DRRXDURECT$0.06-$0.06-$0.12$0.24$6.91 million$2.30 million3/26/2025Q4 2024MTEXMannatechN/A$1.20N/A$1.20N/A$29.01 million3/13/2025Q4 2024EVOKEvoke Pharma-$0.25-$0.49-$0.24-$0.49$3.08 million$3.31 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthDRRXDURECTN/AN/AN/AN/AN/AEVOKEvoke PharmaN/AN/AN/AN/AN/AMTEXMannatech$0.201.89%N/A15.04%N/AUBXUnity BiotechnologyN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioDRRXDURECTN/A0.710.60EVOKEvoke PharmaN/A1.441.39MTEXMannatech0.441.250.74UBXUnity BiotechnologyN/A3.453.45Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipDRRXDURECT28.03%EVOKEvoke PharmaN/AMTEXMannatech12.98%UBXUnity Biotechnology29.49%Insider OwnershipCompanyInsider OwnershipDRRXDURECT3.20%EVOKEvoke Pharma2.29%MTEXMannatech41.50%UBXUnity Biotechnology5.80%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableDRRXDURECT8031.04 million30.05 millionOptionableEVOKEvoke Pharma41.49 million1.40 millionNot OptionableMTEXMannatech2501.90 million1.10 millionNot OptionableUBXUnity Biotechnology6017.21 million15.87 millionOptionableEVOK, UBX, DRRX, and MTEX HeadlinesRecent News About These CompaniesBay Area biotech company Unity lays off every single worker, including CEOMay 7 at 12:20 AM | msn.comBay Area biotech company Unity, once worth $700M, lays off entire remaining workforceMay 5 at 10:11 PM | msn.comSouth San Francisco biotech company lays off entire workforce, including CEOMay 5 at 10:11 PM | msn.comUnity disbands workforce as it searches for strategic path forward, while Mammoth cuts 24 rolesMay 5 at 5:10 PM | fiercebiotech.comUNITY Biotechnology to Present at the ARVO 2025 Annual MeetingMay 1, 2025 | globenewswire.comChardan Capital Has Negative Outlook of UBX FY2025 EarningsApril 28, 2025 | americanbankingnews.comNEJM Evidence publishes results from Phase 2 BEHOLD study of UBX1325April 25, 2025 | ophthalmologytimes.comUNITY Biotechnology, Inc. Reports First Quarter 2025 Financial Results and Business UpdatesApril 22, 2025 | globenewswire.comUnity Biotechnology price target lowered to $4 from $8 at H.C. WainwrightMarch 26, 2025 | markets.businessinsider.comUnity Biotechnology price target lowered to $4 from $6 at ChardanMarch 26, 2025 | markets.businessinsider.comUnity Biotechnology announces results from ASPIRE Phase 2b study in DMEMarch 25, 2025 | markets.businessinsider.comUnity reports topline outcomes from trial of diabetic macular oedema therapyMarch 25, 2025 | msn.comUNITY Biotechnology tanks on mixed results for eye disease drugMarch 25, 2025 | thepharmaletter.comUBX Stock Down 29% on Mixed Results From Phase II Eye Disease StudyMarch 25, 2025 | zacks.comUNITY Biotechnology Shares Drop 33% After Phase 2b Trial Data on UBX1325 in Diabetic Macular EdemaMarch 24, 2025 | finance.yahoo.comUnity Biotechnology releases topline results from phase 2b ASPIRE trial of UBX1325 in patients with diabetic macular edemaMarch 24, 2025 | ophthalmologytimes.comUNITY Biotechnology tanks after failing to meet goal in eye disorder treatment trialMarch 24, 2025 | msn.comUnity Biotechnology Unveils Mixed Data From Study For Diabetes-Related Blindness, Stock FallsMarch 24, 2025 | benzinga.comUNITY Biotechnology Announces Topline Results from the ASPIRE Phase 2b Study in Diabetic Macular EdemaMarch 24, 2025 | globenewswire.comUNITY Biotechnology to Host Virtual Investor Event to Discuss 24- and 36-Week Data from the Phase 2b ASPIRE Study of UBX1325 in Patients with Diabetic Macular Edema (DME) on March 24, 2025March 23, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesAre Tariffs Threatening Disney’s Comeback Story?By Jea Yu | April 9, 2025View Are Tariffs Threatening Disney’s Comeback Story?Archer Aviation Gets Analyst Target Upgrade: Time to Load Up?By Jeffrey Neal Johnson | April 25, 2025View Archer Aviation Gets Analyst Target Upgrade: Time to Load Up?Why D-Wave's Project With Davidson Is a Game-Changer For QuantumBy Nathan Reiff | April 30, 2025View Why D-Wave's Project With Davidson Is a Game-Changer For Quantum5 Highest-Rated Dividend Stocks According to MarketBeatBy Thomas Hughes | April 10, 2025View 5 Highest-Rated Dividend Stocks According to MarketBeatAnalysts See $4,000 Gold: 3 Ways to Invest at Varied Risk LevelsBy Leo Miller | May 2, 2025View Analysts See $4,000 Gold: 3 Ways to Invest at Varied Risk LevelsEVOK, UBX, DRRX, and MTEX Company DescriptionsDURECT NASDAQ:DRRX$0.64 +0.06 (+10.81%) As of 03:51 PM EasternDURECT Corporation, a biopharmaceutical company, develops medicines based on its epigenetic regulator program. The company's lead product larsucosterol (DUR-928), an endogenous, orally bioavailable small molecule that is in Phase IIb clinical trial to play a regulatory role in lipid metabolism, stress and inflammatory responses, and cell death and survival to treat alcohol-associated hepatitis, as well as completed Phase Ib clinical trial to treat patients with nonalcoholic steatohepatitis. It also offers ALZET product line that consists of osmotic pumps and accessories used for research in mice, rats, and other laboratory animals. In addition, the company offers POSIMIR, a post-surgical pain product to deliver bupivacaine over three days in adults; and Methydur to treat attention deficit hyperactivity disorder. It markets and sells its ALZET lines through direct sales force in the United States, as well as through a network of distributors in other countries. The company has strategic collaboration and other agreements with Virginia Commonwealth University Intellectual Property Foundation; Indivior UK Ltd.; and Innocoll Pharmaceuticals Limited. DURECT Corporation was incorporated in 1998 and is headquartered in Cupertino, California.Evoke Pharma NASDAQ:EVOK$3.23 +0.12 (+3.86%) Closing price 03:59 PM EasternExtended Trading$3.23 0.00 (0.00%) As of 07:18 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Evoke Pharma, Inc., a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults. The company markets its products to gastroenterologists, internal medicine specialists, primary care physicians, and select health care providers. Evoke Pharma, Inc. was incorporated in 2007 and is headquartered in Solana Beach, California.Mannatech NASDAQ:MTEX$10.59 +0.59 (+5.90%) Closing price 03:58 PM EasternExtended Trading$10.00 -0.59 (-5.57%) As of 07:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Mannatech, Incorporated operates as a health and wellness company in the Americas, Europe, the Middle East, Africa, and the Asia-Pacific. The company develops, markets, and sells nutritional supplements; topical and skin care, and anti-aging products; and weight-management and fitness products. It primarily sells its products directly, as well as through e-commerce and network marketing channels. Mannatech, Incorporated was incorporated in 1993 and is headquartered in Flower Mound, Texas.Unity Biotechnology NASDAQ:UBX$0.90 +0.01 (+0.91%) Closing price 03:58 PM EasternExtended Trading$0.94 +0.04 (+4.22%) As of 07:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Unity Biotechnology, Inc., a biotechnology company, engages in the research and development of therapeutics to slow, halt, or reverse diseases of aging. The company's lead drug candidate includes UBX1325, which is Phase 2 clinical trial for the treatment of age-related diseases of the eye, including diabetic macular edema, age-related macular degeneration, and diabetic retinopathy. It also develops UBX1967 for the treatment of ophthalmologic diseases; UBX2048, a Tie2/VEGF bispecific; UBX2050, a human anti-Tie2 agonist monoclonal antibody for the treatment of eye diseases; and UBX2089, a a-Klotho hormone drug candidate for multiple neurology indications. The company was formerly known as Forge, Inc. and changed its name to Unity Biotechnology, Inc. in January 2015. Unity Biotechnology, Inc. was incorporated in 2009 and is headquartered in South San Francisco, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Is Energy Transfer Undervalued or a Value Trap? Carvana’s Stock Price Rebound Shifts Into a Higher Gear Why Investors Should Be Careful About AMC's Bitcoin Dreams Alphabet Slumps as Apple Eyes AI Search—Is the Sell-Off Overdone? Joby's Q1: Key Milestones Achieved as Path to Market Crystalizes Rockwell Automation: Tailwinds From Onshoring U.S. Production IBM's AI Offensive: Assessing IBM's Path to Renewed Growth Upwork's Earnings Beat Fuels Stock Rally—Is Freelancing Booming? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
